BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tempest Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Tempest Therapeutics's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06680258-2171@assetmemo.bio
DTSTAMP:20261121T010121Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Amezalpat: Phase 3 readout est. (NCT06680258)
DESCRIPTION:Amezalpat\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Study
  of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresect
 able or Metastatic HCC Not Previously Treated With Systemic Therapy\nEstim
 ated primary completion: December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/amezalpat#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06680258
URL:https://assetmemo.bio/drug/amezalpat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
